Personalizing KRAS-Mutant Allele-Specific Therapies

Chiara Falcomatà; Günter Schneider; Dieter Saur

doi:10.1158/2159-8290.CD-19-1261

Personalizing KRAS-Mutant Allele-Specific Therapies

Cancer Discov. 2020 Jan;10(1):23-25. doi: 10.1158/2159-8290.CD-19-1261.

Authors

Chiara Falcomatà^{1

2}, Günter Schneider^{1

3}, Dieter Saur^{4

2

3}

Affiliations

¹ Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
² Chair of Translational Cancer Research and Institute for Experimental Cancer Therapy, Klinikum rechts der Isar, School of Medicine, Technische Universität München, Munich, Germany.
³ Department of Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
⁴ Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany. dieter.saur@tum.de.

PMID: 31919121
DOI: 10.1158/2159-8290.CD-19-1261

Abstract

KRAS ^G12R mutations occur almost exclusively in pancreatic ductal adenocarcinoma. The results of a study that reveals specific differences in KRAS downstream signaling and metabolic rewiring of pancreatic cancer cells harboring KRAS ^G12R mutations promise to improve our possibilities to better stratify patients for individualized therapies.See related article by Hobbs et al., p. 104.

Publication types

Comment

MeSH terms

Alleles
Carcinoma, Pancreatic Ductal / genetics*
Humans
Mutation
Pancreatic Neoplasms / genetics*
Phosphatidylinositol 3-Kinases
Proto-Oncogene Proteins p21(ras)

Substances

KRAS protein, human
Proto-Oncogene Proteins p21(ras)